Oramed Pharmaceuticals Stock EBITDA
| ORMP Stock | 732.90 4.20 0.57% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Oramed Pharmaceuticals' long-term financial health and intrinsic value.
Oramed |
Oramed Pharmaceuticals Company EBITDA Analysis
Oramed Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Oramed Pharmaceuticals EBITDA | (15.43 M) |
Most of Oramed Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oramed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Oramed Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (15.43 Million). This is much lower than that of the sector and significantly lower than that of the EBITDA industry. The ebitda for all Israel stocks is notably higher than that of the company.
Oramed EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.Oramed Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Oramed Fundamentals
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 | |||
| Operating Margin | (584.92) % | |||
| Current Valuation | 156.33 M | |||
| Shares Outstanding | 17.38 M | |||
| Price To Book | 866.13 X | |||
| Revenue | 2.64 M | |||
| Gross Profit | 2.54 M | |||
| EBITDA | (15.43 M) | |||
| Net Income | (15 M) | |||
| Cash And Equivalents | 26.19 M | |||
| Cash Per Share | 1.51 X | |||
| Current Ratio | 5.10 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (14.32 M) | |||
| Earnings Per Share | (0.87) X | |||
| Number Of Employees | 10 | |||
| Beta | 1.23 | |||
| Market Capitalization | 189.3 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Oramed Stock
When determining whether Oramed Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oramed Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oramed Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Oramed Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Oramed Stock refer to our How to Trade Oramed Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.